KEY-T 0.18 BIP.UN-T -0.15 POW-T -0.1 BBD.B-T 1.53 UNH-N -5.61 NTR-T 0.52 TGT-N 1.27
Geoff Houlton
The ultimate 360° Tracker Your financial life in one place, automatically

Geoff Houlton

Senior Healthcare Analyst. at Union Securities

Member since: Mar '08 · 7 Opinions

UnlockRating

Rating Card

premium

Unlock Expert's Rating and Top Picks Portfolio

Curated by Michael O'Reilly since 2020
1550+ opinions with 4.81 rating (one of the best performing expert)

Latest Top Picks

Unlock Geoff's portfolio

Stock Opinions by Geoff Houlton

TRADE

Sophiris Bio(SHS-T)

Mar 26, 2008
A drug that corrects complications that occur with the prostrate and prostrate cancer. Entering phase 2 clinical trials, has large market opportunities. Have done safety studies. In good shape regarding their cash position.
Geoff HoultonGeoff Houlton
Unknown
Unlock Rating
$0.840

Stock price when the opinion was issued

Consumer Products
BUY

Zoomed(ZMD-X)

Mar 26, 2008
Has raised capital. Produces a hand held company to assist primary care physicians, to help electronic prescribing. It doesn’t cost the physician anything. The company is doing very well.
Geoff HoultonGeoff Houlton
Unknown
Unlock Rating
$0.370

Stock price when the opinion was issued

electrical electronic
BUY

Covalon Technologies(COV-X)

Mar 26, 2008
Has done tremendously well. They focus on wound care products, and coatings for products. The company has tremendous potential, they signed a deal with a large British company. Great opportunity, going to do well going forward.
Geoff HoultonGeoff Houlton
Unknown
Unlock Rating
$2.640

Stock price when the opinion was issued

medical services
BUY

Telesta Therapeutics Inc(TST-T)

Mar 26, 2008
A very interesting company. Has an animal health product, human health products focused on bladder cancer and a vaccine for cattle. Likes the company, has existing products (short-term revenue stream) and has future opportunity and a potential blockbuster product. A significant opportunity.
Geoff HoultonGeoff Houlton
No
Unlock Rating
$0.920

Stock price when the opinion was issued

biotechnology pharmaceutical
WEAK BUY

Microbix Biosystems(MBX-T)

Mar 26, 2008
Been around for a long time. Has a broad range of technologies. Have recently signed licensed for Virusmax, which can double the yield of virus production for vaccinations. Bull semen-sexing technology. Have some very interesting technologies. Watching it very closely. Like the company.
Geoff HoultonGeoff Houlton
No
Unlock Rating
$0.760

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Healthscreen Solutions Inc.(MDU-X)

Mar 26, 2008
Focuses on providing software for doctors, directed at Primary physicians. Have lots of new products coming through. Great opportunity.
Geoff HoultonGeoff Houlton
No
Unlock Rating
$0.295

Stock price when the opinion was issued

computer software processing
TOP PICK

YM BioSciences(YM-T)

Mar 26, 2008
Recently suffered when phase 3 testing failed. Has cash in the bank, has a long runway (cash on a burn rate). Have 2 products in phase 3, one of which is approved in India and China. Great opportunities. Way undervalued.
Geoff HoultonGeoff Houlton
No
Unlock Rating
$0.990

Stock price when the opinion was issued

biotechnology pharmaceutical
Showing 1 to 7 of 7 entries
  • «
  • ‹
  • 1
  • ›
  • »

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Latest Buy Signals

CLS-T -3.91$123.45
NVDA-Q 4.58$111.01
PEP-Q -1.93$133.38
IBM-N 3.08$232.41
RMD-N -0.22$235.88

Today's Top Picks

KEY-T 0.18$42.62
BIP.UN… -0.15$39.97
POW-T -0.1$50.8
BBD.B-… 1.53$91.21
UNH-N -5.61$418.64

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

ARE-T -0.27$15.4
CVX-N -0.34$138.73
XOM-N -0.06$108.57
CNQ-T -0.01$40.68
TD-T -0.03$86.17

Most Recent Experts

Greg Newman

Scotia Wealth Management

Stockchase Insights

5i Research

Jim Cramer - Mad Money

CNBC

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

© Stockchase Inc.